Recent news by Business Insider point to Amazon’s ambition to expand its focus into Life Sciences and drug discovery, leveraging its artificial intelligence (AI) capabilities, cloud infrastructures, and other “high-tech” assets. As per data obtained by Business Insider from an internal AI conference, Amazon executives discuss using machine learning to revolutionize drug discovery, genomics, clinical trials, and more.
It is impossible to deny the increasing impact that “big tech” giants, like Google, Microsoft, Tencent, and others, have on the Life Sciences industry. All of us have heard of DeepMind’s success in solving protein structures with AlphaFold, and this technology developed by Alphabet’s subsidiary has become a game changer for the pharmaceutical industry, at least conceptually -- illustrating what is possible and where the application of high-tech to fundamental biology problems, may lead us at some point.
And just days ago, Meta (formerly Facebook) did just that -- researchers from this California-based social media giant have used AI to predict the structures of some 600 million proteins from bacteria, viruses, and other microorganisms that haven’t been characterized. They used a ‘large language model,’ a type of AI that can predict text from just a few letters or words.
So, what attracts technological giants into the Life Sciences market?